Physicochemical Properties
| Molecular Formula | C3H6NA2O6S2 |
| Molecular Weight | 248.17 |
| Exact Mass | 247.94 |
| CAS # | 36589-58-9 |
| Related CAS # | 21668-77-9;36589-58-9 (Sodium);36589-58-9 (Disodium); |
| PubChem CID | 6451143 |
| Appearance | White to off-white solid powder |
| Density | 1.773 g/cm3 |
| Melting Point | >300°C |
| LogP | 0.628 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 13 |
| Complexity | 227 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | S(C([H])([H])C([H])([H])C([H])([H])S(=O)(=O)[O-])(=O)(=O)[O-].[Na+].[Na+] |
| InChi Key | DKGJFKPIUSHDIT-UHFFFAOYSA-L |
| InChi Code | InChI=1S/C3H8O6S2.2Na/c4-10(5,6)2-1-3-11(7,8)9;;/h1-3H2,(H,4,5,6)(H,7,8,9);;/q;2*+1/p-2 |
| Chemical Name | disodium;propane-1,3-disulfonate |
| Synonyms | Eprodisate Disodium Kiacta Eprodisate sodium |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Additional Infomation | Eprodisate Disodium is the orally available disodium salt form of eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis. Upon administration, eprodisate competitively binds to the glycosaminoglycan binding sites on serum amyloid A (SAA), which inhibits the formation of the glycosaminoglycan-amyloid fibril aggregate. This prevents the formation of amyloid deposits in certain organs, especially the kidneys, in AA amyloidosis. |
Solubility Data
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~201.46 mM) DMSO : ~7.69 mg/mL (~30.98 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.77 mg/mL (3.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.77 mg/mL (3.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 0.77 mg/mL (3.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 100 mg/mL (402.92 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0295 mL | 20.1475 mL | 40.2950 mL | |
| 5 mM | 0.8059 mL | 4.0295 mL | 8.0590 mL | |
| 10 mM | 0.4029 mL | 2.0147 mL | 4.0295 mL |